创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

HAN Yanzhen, XUE Jianpeng, HU Jialiang, XU Hanmei. Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 129-137.
Citation: HAN Yanzhen, XUE Jianpeng, HU Jialiang, XU Hanmei. Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 129-137.

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

  • Matrix metalloproteinases (MMPs) are a group of zinc and calcium dependent proteolytic enzymes that degrade extracellular matrix and basement membrane. They play very important roles in the processes of tumor angiogenesis, metastasis and invasion. MMP inhibitors (MMPIs) have become the focus of anticancer agents R & D. This paper reviewed the progress in clinical development of MMPIs as anticancer agents, so as to provide references for their further investigation and application.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return